Summary
Celiprolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Atrial Fibrillation would be drug repurposing rather than first-in-human development. This does not mean it is approved for Atrial Fibrillation. No registered clinical trial in this database tests Celiprolol specifically in Atrial Fibrillation. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 3 publications for this pair: 3 clinical trial publications. Publication years run from 1986 to 1987. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Atrial Fibrillation ranks 332 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous reversion to sinus rhythm occurs in ~50% of paroxysmal AF within 24-48 hours; persistent AF almost never self-terminates; rate-control (the dominant strategy) by definition keeps the patient in AF.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 26.0 (trials 0.0, literature 6.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (3 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | agonist |
| Data sources | DGIdb |
| Linked via biomarker / target | ADRB2 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Celiprolol to Atrial Fibrillation in the current OSMF trial extract.
Published literature
- Clinical trial publication Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillationAtwood JE, Sullivan M, Forbes S et al. · Journal of the American College of Cardiology · 1987 · PMID 2885354
- Clinical trial publication Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillationMyers J, Atwood JE, Sullivan M et al. · Journal of applied physiology (Bethesda, Md. : 1985) · 1987 · PMID 2887542
- Clinical trial publication Effect of orally administered celiprolol in patients with chronic atrial fibrillationLin SK, Morganroth J, Heng M et al. · Journal of cardiovascular pharmacology · 1986 · PMID 2427838
Mechanism and notes
Recorded mechanism or class: agonist.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRB2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Celiprolol approved for Atrial Fibrillation?
Celiprolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Atrial Fibrillation would be drug repurposing rather than first-in-human development. This does not mean it is approved for Atrial Fibrillation. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Celiprolol in clinical trials for Atrial Fibrillation?
No registered clinical trial in this database tests Celiprolol specifically in Atrial Fibrillation. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Celiprolol in Atrial Fibrillation?
The record for Celiprolol in Atrial Fibrillation rests on 3 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRB2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.